10.60
price down icon8.62%   -1.00
after-market Handel nachbörslich: 11.34 0.74 +6.98%
loading

Cybin Inc Aktie (CYBN) Neueste Nachrichten

pulisher
Nov 18, 2024

Cybin (NYSE:CYBN) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Cybin Reports Positive Phase 2 Data for CYB003 - The Dales Report

Nov 18, 2024
pulisher
Nov 18, 2024

Cybin’s CYB003 Shows Promising Results for Depression - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Yahoo Finance

Nov 18, 2024
pulisher
Nov 14, 2024

Cybin posts second-quarter loss widens as clinical trials advance - Green Market Report

Nov 14, 2024
pulisher
Nov 14, 2024

Canaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - BioSpace

Nov 14, 2024
pulisher
Nov 14, 2024

Cybin to Present Promising CYB003 Study Results - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Cybin to Showcase Promising Depression Treatment Progress - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Cybin Phase 3 Layout - Green Market Report

Nov 14, 2024
pulisher
Nov 13, 2024

CYBNCybin Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Cybin launches new program phase to treat Major Depressive Disorder | 2024-11-13 | Investing News - Stockhouse Publishing

Nov 13, 2024
pulisher
Nov 13, 2024

Cybin’s Phase 3 Trials and Financial Update - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - StreetInsider.com

Nov 13, 2024
pulisher
Nov 13, 2024

Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results – Company AnnouncementFT.com - Financial Times

Nov 13, 2024
pulisher
Nov 12, 2024

What might RFK Jr’s psychedelic strategy look like? - Proactive Investors USA

Nov 12, 2024
pulisher
Nov 08, 2024

Cybin Faces Key Data Readouts For Major Depressive Disorder, Generalized Anxiety Disorder - RTTNews

Nov 08, 2024
pulisher
Nov 08, 2024

Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 06, 2024

Cybin Inc. (NYSE:CYBN) Stake Lowered by Rosalind Advisors Inc. - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Cybin (OTCMKTS:CYBN) Trading Up 0.2%Here's What Happened - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Cybin, Inc.Why Compass Pathways Is No Compass for Cybin's Progression Prospects - Smartkarma

Nov 05, 2024
pulisher
Nov 04, 2024

PDS Planning Inc Sells 885,540 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha

Nov 03, 2024
pulisher
Oct 31, 2024

Cybin to Participate at the 2024 Milken Institute Future of Health Summit - BioSpace

Oct 31, 2024
pulisher
Oct 31, 2024

Cybin to Highlight Innovations at Health Summit - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Oct 31, 2024
pulisher
Oct 28, 2024

(CYBN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 25, 2024

EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program - MSN

Oct 25, 2024
pulisher
Oct 24, 2024

Cybin secures patent for CNS disorder treatment candidates - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Cybin announces grant of patent in support of CYB005 phenethylamines program - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Business Wire

Oct 24, 2024
pulisher
Oct 22, 2024

$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds

Oct 22, 2024
pulisher
Oct 22, 2024

Sanctuary Advisors LLC Makes New Investment in Cybin Inc. (NYSE:CYBN) - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Cybin (NYSE:CYBN) Trading Down 7.4%What's Next? - MarketBeat

Oct 21, 2024
pulisher
Oct 18, 2024

Cybin (NYSE:CYBN) Stock Price Up 9.7%What's Next? - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor + - Seeking Alpha

Oct 18, 2024
pulisher
Oct 17, 2024

(CYBN) Trading Signals - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 15, 2024

Cybin: Top Value Psychedelic Stock (NYSE:CYBN) - Seeking Alpha

Oct 15, 2024
pulisher
Oct 14, 2024

Cybin (NYSE:CYBN) Shares Gap DownWhat's Next? - MarketBeat

Oct 14, 2024
pulisher
Oct 12, 2024

Cybin (OTCMKTS:CYBN) Trading 1.5% HigherHere's What Happened - MarketBeat

Oct 12, 2024
pulisher
Oct 10, 2024

Cybin (NYSE:CYBN) Shares Up 5.4%Still a Buy? - MarketBeat

Oct 10, 2024
pulisher
Oct 07, 2024

(CYBN) Investment Analysis and Advice - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 03, 2024

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat - MSN

Oct 03, 2024
pulisher
Oct 03, 2024

Cybin Inc. CEO to Speak at Research Event - TipRanks

Oct 03, 2024
pulisher
Oct 03, 2024

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 - StockTitan

Oct 03, 2024
pulisher
Oct 02, 2024

Cybin (NYSE:CYBN) Trading Down 4.8% - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Cybin gears up for Phase 3 trial in depression treatment By Investing.com - Investing.com South Africa

Oct 02, 2024
pulisher
Oct 01, 2024

Cybin gears up for Phase 3 trial in depression treatment - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Cybin Gears Up for Global Phase 3 Depression Trial - TipRanks

Oct 01, 2024
pulisher
Oct 01, 2024

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program - Yahoo Finance

Oct 01, 2024
pulisher
Sep 27, 2024

Cybin (NYSE:CYBN) Shares Gap Down to $9.88 - MarketBeat

Sep 27, 2024
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):